Advertisement

Advertisement

2020 ASH Annual Meeting & Exposition

Immunotherapy
Hematologic Malignancies

Bispecific Antibody Platform: Early Data in Relapsed and Refractory Myeloma

“There was never a night or a problem that could defeat sunrise or hope.” —Bernard Williams To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (...

Hematologic Malignancies
Supportive Care

Study Finds Tranexamic Acid Unable to Prevent Bleeding in Patients With Hematologic Malignancies

In the first randomized trial to evaluate prophylactic antifibrinolytic therapy in patients with hematologic malignancies, tranexamic acid failed to reduce bleeding or the need for transfusion vs plac...

Multiple Myeloma
Immunotherapy

Belantamab Mafodotin-blmf Plus Pomalidomide and Dexamethasone Elicits Responses in Myeloma

Belantamab mafodotin-blmf combined with pomalidomide and dexamethasone led to a very good partial response or better in approximately three-quarters of patients with multiple myeloma that was double-c...

Leukemia

Studies Provide Guidance on the Use of Blinatumomab in Pediatric Acute Lymphoblastic Leukemia

Monotherapy with blinatumomab as consolidation therapy before allogeneic stem cell transplant appears to be the optimal treatment for children with high-risk first-relapse B-cell precursor acute lymph...

Hematologic Malignancies

Novel Therapies Under Study in Chronic Myeloid Leukemia

“There is progress whether ye are going forward or backward! The thing is to move.” —Edgar Cayce To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematolo...

Hematologic Malignancies

In Case You Missed It: Brief Highlights From ASH 2020

In case you missed these while attending the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, below is a sampler of highlights that were not included in our first round of m...

Hematologic Malignancies

SIMPLIFY Trials: JAK Inhibitor Yields Long-Term Survival Benefit and Transfusion Independence in Myelofibrosis

Treatment with the novel JAK inhibitor momelotinib led to long-term overall survival and sustained transfusion independence in patients with intermediate- or high-risk myelofibrosis, according to upda...

Leukemia

Novel Approaches in Chronic Lymphocytic Leukemia

To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting pr...

Lymphoma
Immunotherapy

B-Cell and T-Cell Non-Hodgkin Lymphomas

To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting pr...

Hematologic Malignancies
Supportive Care
Symptom Management

Ruxolitinib Improves Outcomes in Steroid-Refractory or Steroid-Dependent Graft-vs-Host Disease

Ruxolitinib was superior to best available therapy in achieving efficacy as determined by best overall response and duration of response, with acceptable safety in adolescents and adults with steroid-...

Myelodysplastic Syndromes
Geriatric Oncology

Transplant May Improve Survival in Older Patients With High-Risk Myelodysplastic Syndrome

Stem cell transplants are not frequently offered to older patients with high-risk myelodysplastic syndromes (MDS). According to a study from the Blood and Marrow Transplant Clinical Trials Network (BM...

Multiple Myeloma
Immunotherapy

DREAMM-2 Analysis: Number of Prior Treatments No Hindrance to Efficacy of Belantamab Mafodotin-blmf

A post hoc analysis of the phase II DREAMM-2 trial showed single-agent belantamab mafodotin-blmf to be efficacious and tolerable in patients with relapsed or refractory multiple myeloma treated with a...

Multiple Myeloma
Immunotherapy

Belantamab Mafodotin-blmf Plus Pomalidomide and Dexamethasone Elicits Responses in Myeloma

Belantamab mafodotin-blmf combined with pomalidomide and dexamethasone led to a very good partial response (VGPR) or better in approximately three-quarters of patients with multiple myeloma that was d...

Multiple Myeloma
Immunotherapy

Expert Point of View: Ajay K. Nooka, MD, MPH, FACP

Ajay K. Nooka, MD, MPH, FACP, Associate Professor of Hematology and Medical Oncology at Emory University and Medical Director, Winship Research Informatics Shared Resource at Winship Cancer Institute,...

Multiple Myeloma
Immunotherapy

New Targets Explored for Bispecific T-Cell–Engaging Antibodies in Myeloma

B-cell maturation antigen (BCMA) is the most frequent target of immunotherapies in relapsed or refractory multiple myeloma, but bispecific T-cell–engaging antibodies with novel targets are also achiev...

Multiple Myeloma
Immunotherapy

Expert Point of View: Sagar Lonial, MD, FACP

Sagar Lonial, MD, FACP, the Anne and Bernard Gray Family Chair in Cancer, Chair and Professor of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, commented on the APOLLO ...

Multiple Myeloma
Immunotherapy

Subcutaneous Daratumumab Meets Primary Endpoint in APOLLO Trial in Myeloma

The first phase III study to evaluate the subcutaneous form of daratumumab has met its primary endpoint, investigators of the APOLLO trial reported at the 2020 American Society of Hematology (ASH) Ann...

Leukemia
Lymphoma

Treatment With LOXO-305 Results in Durable Efficacy in Heavily Pretreated Patients With CLL/SLL

Despite the marked efficacy of ibrutinib, acalabrutinib, and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), treatment failure can occur through the development of res...

Lymphoma
Immunotherapy

Expert Point of View: Marco Ruella, MD

Marco Ruella, MD, of Perelman School of Medicine and Scientific Director of the Lymphoma Program, University of Pennsylvania, commented on this study on CD58 aberrations: “This is a very important stu...

Lymphoma
Immunotherapy

Expert Point of View: James Essell, MD

James Essell, MD, Medical Director of the Blood Cancer Center, The Jewish Hospital-Mercy Health Cincinnati Cancer and Cellular Therapy Center, and Chair of Cellular Therapy, observed that axicabtagene...

Lymphoma
Immunotherapy

ZUMA-5: Axicabtagene Ciloleucel Elicits Response in Indolent Non-Hodgkin Lymphoma

In the phase II ZUMA-5 trial, the cellular immunotherapy axicabtagene ciloleucel led to responses in 92% of patients with indolent non-Hodgkin lymphoma (NHL), researchers reported at the 2020 American...

Leukemia
Issues in Oncology

Study Finds Survival Disparities and Mutational Differences for Black Patients Younger Than 60 With AML

It has been well documented that, collectively, Black individuals have the highest death rates and shortest survival of any racial/ethnic group in the United States for most cancers. Black men also ha...

Expert Point of View: David Snyder, MD

David Snyder, MD, Acting Chair, City of Hope Department of Hematology & Hematopoietic Cell Transplantation, Duarte, California, who was not involved in the ASCEMBL study, commented on the promise ...

Leukemia

Study Finds Asciminib Safer, More Effective Than Bosutinib in Chronic-Phase CML

Since the introduction of imatinib almost 18 years ago, similar next-generation tyrosine kinase inhibitors have been approved for chronic myeloid leukemia (CML), including dasatinib, nilotinib, bosuti...

Leukemia
Lymphoma
Multiple Myeloma
Immunotherapy

ASH 2020 Meeting Highlights

The world of hematologic malignancies continues to move forward at a robust pace despite the challenges of the COVID era. Although some areas of clinical trials and basic research suffered short-term ...

Hematologic Malignancies

SIMPLIFY Trials: JAK Inhibitor Yields Long-Term Survival Benefit and Transfusion Independence in Myelofibrosis

Treatment with the novel JAK inhibitor momelotinib led to long-term overall survival and sustained transfusion independence in patients with intermediate- or high-risk myelofibrosis, according to upda...

Multiple Myeloma
Immunotherapy

Novel Insights Into Multiple Myeloma

“Knowledge has a beginning but no end.” —Geeta Iyengar To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, ...

COVID-19

COVID Virus–Specific T Cells: Potential Treatment of Severe COVID-19 Infection Under Study

It may be possible to exploit T cells from healthy volunteers who have recovered from COVID-19 as a treatment for this viral infection. Researchers at the Center for Cell and Gene Therapy at Baylor Co...

Lymphoma

Expert Point of View: Deepa Jagadeesh, MD, MPH

In commenting on the results of the phase II PRIMO trial of the PI3K inhibitor duvelisib by Pro et al, Deepa Jagadeesh, MD, MPH, Assistant Professor, Cleveland Clinic Lerner College of Medicine, Lymph...

Lymphoma

Phase II PRIMO Dose-Optimization Trial of Duvelisib in Peripheral T-Cell Lymphoma

Researchers at the ASH Annual Meeting and Exposition reported high response rates in patients with relapsed peripheral T-cell lymphoma after treatment with single-agent duvelisib, a dual PI3K inhibito...

Lymphoma

Expert Point of View: Deepa Jagadeesh, MD, MPH

“Although some B-cell lymphomas are highly curable, this goal remains elusive for most T-cell lymphomas (TCL). Refractory and relapsed disease post induction therapy remains a major challenge in manag...

Lymphoma

Allogeneic Stem Cell Transplant Improves Survival in Peripheral T-Cell Lymphoma

In a large retrospective analysis of allogeneic transplant for relapsed or refractory peripheral T-cell lymphoma (PTCL), more than half the patients studied were alive at 5 years, investigators report...

Lymphoma
Immunotherapy

Expert Point of View: James Essell, MD

James Essell, MD, Medical Director of the Blood Cancer Center, The Jewish Hospital-Mercy Health Cincinnati Cancer and Cellular Therapy Center, and Chair of Cellular Therapy, observed that axicabtagene...

Lymphoma
Immunotherapy

ZUMA-5: Axicabtagene Ciloleucel Elicits Response in Indolent Non-Hodgkin Lymphoma

In the phase II ZUMA-5 trial, the cellular immunotherapy axicabtagene ciloleucel led to responses in 92% of patients with indolent non-Hodgkin lymphoma (NHL), researchers reported at the 2020 American...

Leukemia

MURANO Trial: Venetoclax Plus Rituximab Achieves Durable Progression-Free Survival in Resistant CLL

Patients with relapsed or refractory chronic lymphocytic leukemia (CLL) treated with the combination of fixed-duration venetoclax/rituximab had a longer overall survival and progression-free survival ...

Hematologic Malignancies
Immunotherapy

Early Research Explores Relationship Between CD58 Loss and Resistance to CAR T-Cell Therapies

Engineering chimeric antigen receptor (CAR) T cells to overcome CD58 loss may be a way to boost responses in patients with diffuse large B-cell lymphoma (DLBCL) who do not respond to treatment with ax...

Multiple Myeloma
Immunotherapy

Expert Point of View: Sagar Lonial, MD, and Adam D. Cohen, MD

The studies of ALLO-715 “off-the-shelf” CAR T-cell therapy and bb21217 impressed two experts in the field. Sagar Lonial, MD, the Anne and Bernard Gray Family Chair in Cancer, Chair and Professor of He...

Multiple Myeloma
Immunotherapy

Novel Anti-BCMA CAR T-Cell Therapies Show Activity in Myeloma

In the treatment of relapsed or refractory multiple myeloma, chimeric antigen receptor (CAR) T-cell therapies with unique characteristics, still targeting B-cell maturation antigen (BCMA), are looking...

Leukemia

Expert Point of View: Marlise Luskin, MD

Commenting on this trial, Marlise Luskin, MD, of Dana-Farber Cancer Institute, Boston, explained that the treatment of AML in older adults remains a particular challenge for leukemia clinicians. “Alth...

Leukemia

Oral Azacitidine Is Noninferior to Placebo for Health-Related Quality of Life in AML

Health-related quality of life was sustained in patients taking oral azacitidine (also known as CC-486) compared with placebo in patients with acute myeloid leukemia (AML), according to results of the...

Multiple Myeloma

Expert Point of View: Suzanne Lentzsch, MD, PhD

IFM 2009 showed that autologous stem cell transplant (ASCT) combined with lenalidomide, bortezomib, and dexamethasone (RVd) results in a significantly better progression-free survival than RVd alone i...

Multiple Myeloma

Long-Term Follow-up of IFM 2009 Confirms Benefit of Front-Line Transplant in Myeloma

The benefit of autologous transplantation in newly diagnosed multiple myeloma has been confirmed by follow-up of the IFM 2009 trial, reported at the 2020 American Society of Hematology (ASH) Annual Me...

Multiple Myeloma
Immunotherapy

Belantamab Mafodotin-blmf in Multiple Myeloma: Number of Prior Treatments No Hindrance to Efficacy

A post hoc analysis of the phase II DREAMM-2 trial showed single-agent belantamab mafodotin-blmf to be efficacious and tolerable in patients with relapsed  or refractory multiple myeloma treated with ...

Multiple Myeloma
Immunotherapy

Expert Point of View: Ajay K. Nooka, MD, MPH

Ajay K. Nooka, MD, MPH, Associate Professor of Hematology and Medical Oncology at Emory University and Medical Director, Winship Research Informatics Shared Resource at Winship Cancer Institute, Atlan...

Multiple Myeloma
Immunotherapy

New Targets Explored for Bispecific T-Cell–Engaging Antibodies in Myeloma

B-cell maturation antigen (BCMA) is the most frequent target of immunotherapies in relapsed or refractory multiple myeloma, but bispecific T-cell–engaging (BiTE) antibodies with novel targets are also...

Multiple Myeloma
Immunotherapy

Expert Point of View: Sagar Lonial, MD

Sagar Lonial, MD, the Anne and Bernard Gray Family Chair in Cancer, Chair and Professor of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, commented on the APOLLO trial ...

Multiple Myeloma
Immunotherapy

Subcutaneous Daratumumab Meets Primary Endpoint in APOLLO Trial in Myeloma

The first phase III study to evaluate the subcutaneous form of daratumumab has met its primary endpoint, investigators of the APOLLO trial reported at the 2020 American Society of Hematology (ASH) Ann...

leukemia
genomics/genetics

Sara Zarnegar-Lumley, MD, on AML: Prognostic Effects of IDH Mutations

Sara Zarnegar-Lumley, MD, of Vanderbilt University Medical Center, discusses an analysis of a large cohort confirming the age-associated prevalence of IDH mutations in patients, across the age spectru...

hematologic malignancies
lymphoma
multiple myeloma
issues in oncology
palliative care

Lena E. Winestone, MD, MSHP, on Health-Care Disparities in Hematologic Cancers: Real-World Data

Lena E. Winestone, MD, MSHP, of the University of California, San Francisco and Benioff Children’s Hospital, reviews different aspects of bias in treatment delivery, including patient selection for cl...

leukemia
genomics/genetics

Christian Marinaccio, PhD Candidate: Genetic Driver May Play a Role in Progression of Myeloproliferative Neoplasms to AML

Christian Marinaccio, PhD Candidate, of Northwestern University, describes research he is conducting in the laboratory of John D. Crispino, PhD, which shows the loss of the tumor suppressor gene LKB1/...

Advertisement

Advertisement



Advertisement